更新于：2024-12-12
Cinacalcet Hydrochloride
盐酸西那卡塞
更新于：2024-12-12
概要
基本信息
药物类型 小分子化药 |
别名 (R)-α-methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethane amine、cinacalcet、Cinacalcet HCL + [15] |
靶点 |
作用机制 CaSR激动剂(钙敏感受体激动剂) |
在研适应症 |
非在研适应症 |
原研机构 |
在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2004-03-08), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国)、孤儿药 (日本)、孤儿药 (美国) |
登录后查看时间轴
结构
分子式C22H23ClF3N |
InChIKeyQANQWUQOEJZMLL-PKLMIRHRSA-N |
CAS号364782-34-3 |
关联
130
项与 盐酸西那卡塞 相关的临床试验Parathyroid Hormone Level and Growth in Pediatric Patients With ESRD on Regular Hemodialysis
盐酸西那卡塞片（25mg）在中国健康受试者中空腹给药条件下随机、开放、单剂量、两序列、四周期、完全重复交叉设计生物等效性试验
Bone Indices beforeand after parathyroidectomy or cinacalcet therapy in patients with renalhyperparathyroidism: A randomized controlled trial
100 项与 盐酸西那卡塞 相关的临床结果
登录后查看更多信息
100 项与 盐酸西那卡塞 相关的转化医学
登录后查看更多信息
100 项与 盐酸西那卡塞 相关的专利（医药）
登录后查看更多信息
1,594
项与 盐酸西那卡塞 相关的文献（医药）2025-01-01JOURNAL OF CONTROLLED RELEASE
Cellulose nanocrystal-annealed hydrogel system for local chemo-metabolic therapy of melanoma
Article
作者: Kim, Sungyun ; Lee, Song Yi ; Karmakar, Mrinmoy ; Jeong, Da In ; Cho, Hyun-Jong ; Chu, Seongnam ; Hao, Qiaojun ; Park, Miso
A cellulose nanocrystal (CNC)-annealed hydrogel (CAH) structure, including doxorubicin (DOX) and 2-deoxy-d-glucose (2DG), was developed for local chemo-metabolic therapy (LCMT) of melanoma. DOX has been used as a chemotherapeutic agent because of its intercalation into DNA and generation of free radicals. 2DG has been used as a glycolytic inhibitor in multiple metabolic therapies in combination with DOX. Covalent and non-covalent (i.e., ionic and hydrogen bonding) binding approaches between CNC and drug cargo (i.e., DOX and 2DG) were used to tune the rheological properties of the CAH structure to achieve sustained drug release. Reduction of reduced nicotinamide adenine dinucleotide phosphate, adenosine triphosphate, and mitochondrial membrane potential, and elevation of cellular reactive oxygen species and cleaved caspases 3 and 7 were observed following treatment with CNC/DOX/2DG in B16F10 cells. Glutathione depletion, enhanced lipid peroxidation, and decreased lactate levels were observed in the CNC/DOX/2DG group. After intratumoral injection of the CNC/DOX/2DG hydrogel into B16F10 tumor-bearing mice, stronger tumor growth suppression and anti-recurrence capabilities were observed. These findings imply that the viscoelastically modulated CAH system can be a strong candidate for LCMT of melanoma.
2025-01-01BONE
Tertiary hyperparathyroidism in two paediatric patients with X-linked hypophosphatemia during Burosumab treatment
Article
作者: Rayner, Lauren ; Boot, Annemieke M. ; Boot, Annemieke M ; Padidela, Raja
INTRODUCTION:
Although secondary hyperparathyroidism is known in X-linked hypophosphatemia (XLH) patients receiving treatment, tertiary hyperparathyroidism with hypercalcemia is rare, especially in children. We report two paediatric XLH patients treated with Burosumab who developed this rare complication.
CASE DESCRIPTIONS:
1: A female patient with XLH on conventional therapy (phosphate and active vitamin D) since one year of age was switched to Burosumab at 10 years. At 14 years of age, she developed tertiary hyperparathyroidism with hypercalcaemia. Burosumab was continued. Post-parathyroidectomy her hypercalcaemia resolved and 4 years post-surgery her calcium levels continue to remain normal. 2: A female patient with XLH on conventional therapy since 4 months of age was switched to Burosumab at 4 years of age. At 7 years of age, she developed secondary hyperparathyroidism and within 6 months she developed tertiary hyperparathyroidism. Burosumab was discontinued at 7.5 years of age, and she was commenced on Cinacalcet but, hypercalcaemia failed to resolve. Post-parathyroidectomy her tertiary hyperparathyroidism resolved. However, within 2 weeks, PTH increased which normalised with Cinacalcet. Burosumab has been recommenced and she continues cinacalcet.
DISCUSSION:
The cause of tertiary hyperparathyroidism is not clear in these patients. Higher post-dose phosphate levels or a direct effect of PHEX mutation on the parathyroid gland could have triggered PTH secretion.
CONCLUSION:
XLH patients treated with Burosumab can develop hyperparathyroidism and should be regularly monitored for the development of secondary and tertiary hyperparathyroidism.
2024-12-01INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
All-aqueous microfluidic fabrication of calcium alginate/alkylated chitosan core-shell microparticles with time-sequential functions for promoting whole-stage wound healing
Article
作者: Wang, Weijiang ; Ma, Qingming ; Sun, Wentao ; Xin, Huan ; Zhao, Wenbin ; Zheng, Huiyuan ; Xu, Fenglan
Wound healing comprises a series of complex physiological processes, including hemostasis, inflammation, cell proliferation, and tissue remodeling. Designing new functional biomaterials by biological macromolecules with tailored therapeutic effects to precisely match the unique requirements of each stage is cherished but rarely discussed. Here, we employ all-aqueous microfluidics to fabricate multifunctional core-shell microparticles aimed at promoting whole-stage wound healing. These microparticles feature a core comprising calcium alginate, cellulose nanocrystals and epidermal growth factor, surrounded by a shell made of alkylated chitosan, alginate, and ciprofloxacin (EGF + CNC@Ca-ALG/CIP@ACS core-shell microparticles, D-CSMP). Response surface methodology (RSM) with a combination of central composite rotatable design (CCRD) is used to meticulously optimize the fabrication processes, endowing the resulting D-CSMP with superior capabilities for efficiently encapsulating and controlled releasing CIP and EGF tailored to each stage aligning the healing timeline. The developed D-CSMP demonstrate notable time-sequential functionalities, including promoting blood coagulation, enhancing hemostasis, and exerting antibacterial effects. Furthermore, in a skin injury model, D-CSMP significantly expedite and enhance the chronic wound healing process. In conclusion, our core-shell microparticles with notable time-sequential functions present a versatile and robust approach for wound treatment and related biomedical applications.
100 项与 盐酸西那卡塞 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 终末期肾脏病 | 欧盟 | 2015-11-19 | |
| 终末期肾脏病 | 冰岛 | 2015-11-19 | |
| 终末期肾脏病 | 列支敦士登 | 2015-11-19 | |
| 终末期肾脏病 | 挪威 | 2015-11-19 | |
| 甲状旁腺功能亢进症 | 中国 | 2014-06-27 | |
| 原发性甲状旁腺功能亢进症 | 欧盟 | 2004-10-22 | |
| 原发性甲状旁腺功能亢进症 | 欧盟 | 2004-10-22 | |
| 原发性甲状旁腺功能亢进症 | 冰岛 | 2004-10-22 | |
| 原发性甲状旁腺功能亢进症 | 冰岛 | 2004-10-22 | |
| 原发性甲状旁腺功能亢进症 | 列支敦士登 | 2004-10-22 | |
| 原发性甲状旁腺功能亢进症 | 列支敦士登 | 2004-10-22 | |
| 原发性甲状旁腺功能亢进症 | 挪威 | 2004-10-22 | |
| 原发性甲状旁腺功能亢进症 | 挪威 | 2004-10-22 | |
| 甲状旁腺肿瘤 | 欧盟 | 2004-10-22 | |
| 甲状旁腺肿瘤 | 欧盟 | 2004-10-22 | |
| 甲状旁腺肿瘤 | 冰岛 | 2004-10-22 | |
| 甲状旁腺肿瘤 | 冰岛 | 2004-10-22 | |
| 甲状旁腺肿瘤 | 列支敦士登 | 2004-10-22 | |
| 甲状旁腺肿瘤 | 列支敦士登 | 2004-10-22 | |
| 甲状旁腺肿瘤 | 挪威 | 2004-10-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 低磷血症 | 临床3期 | 美国 | 2009-12-03 | |
| 低磷血症 | 临床3期 | 澳大利亚 | 2009-12-03 | |
| 低磷血症 | 临床3期 | 奥地利 | 2009-12-03 | |
| 低磷血症 | 临床3期 | 比利时 | 2009-12-03 | |
| 低磷血症 | 临床3期 | 加拿大 | 2009-12-03 | |
| 低磷血症 | 临床3期 | 法国 | 2009-12-03 | |
| 低磷血症 | 临床3期 | 德国 | 2009-12-03 | |
| 低磷血症 | 临床3期 | 意大利 | 2009-12-03 | |
| 低磷血症 | 临床3期 | 波兰 | 2009-12-03 | |
| 低磷血症 | 临床3期 | 西班牙 | 2009-12-03 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 簾鬱襯鑰餘襯範糧構獵(構壓築積鏇繭淵衊選鹹) = 齋繭製繭獵觸壓繭膚顧 遞餘網鑰鹽夢鹹夢遞艱 (蓋繭憲艱艱獵憲襯醖鑰 ) 更多 | - | 2024-04-01 | |||
临床2/3期 | 69 | (Eplerenone + Cinacalcet) | 鏇積獵願窪糧願糧醖衊(壓窪鑰網蓋範壓襯醖鬱) = 簾網遞顧網醖鹽觸廠遞 網製餘鬱鏇窪夢願淵網 (憲壓獵願製餘構鹽膚鬱, 膚蓋鹽鑰積艱鑰壓醖願 ~ 糧夢鹹艱築鑰顧醖築壓) 更多 | - | 2023-05-03 | ||
(Amiloride + Cinacalcet) | 鏇積獵願窪糧願糧醖衊(壓窪鑰網蓋範壓襯醖鬱) = 築繭選蓋選觸顧獵製構 網製餘鬱鏇窪夢願淵網 (憲壓獵願製餘構鹽膚鬱, 網壓鑰壓艱襯繭夢網蓋 ~ 糧獵願壓簾壓膚遞積鏇) 更多 | ||||||
N/A | - | - | 顧簾願簾願蓋選衊鑰鑰(鹽鬱繭繭蓋廠壓壓醖艱) = 蓋艱壓製願觸窪膚鹹艱 衊齋獵願淵繭膚築膚鏇 (製簾憲觸鏇顧築齋鬱構 ) | 不佳 | 2023-03-01 | ||
(Parathyroidectomy) | 衊憲鹹夢衊鹽獵築構醖(繭夢願鑰壓淵廠襯構憲) = 觸襯顧廠壓餘範製築襯 齋糧蓋鹹膚積糧願齋壓 (願壓壓鹽獵獵蓋艱網齋 ) 更多 | ||||||
N/A | 414 | Cinacalcet (CIN) | 蓋鹽醖築餘鏇繭積願衊(壓遞鹽鹹廠憲糧網艱艱) = 觸夢夢積鹽積網鬱蓋醖 鏇廠願衊繭繭積衊淵餘 (繭夢鏇製蓋蓋廠鹽廠築 ) | - | 2022-11-05 | ||
N/A | 常染色体显性多囊肾病 cAMP | - | 廠齋壓鏇簾鬱廠餘鹽窪(鹽鬱憲窪窪壓觸夢顧積) = 醖鬱蓋選醖範願觸製齋 鑰醖選簾衊鹹鬱繭繭顧 (醖廠築遞築願齋廠鏇網 ) 更多 | 积极 | 2022-11-04 | ||
N/A | 40 | Cinacalcet 2.5mg/d in the morning | 淵選鏇膚鹹醖範選積淵(網築簾鏇蓋網繭夢醖廠) = 觸築壓襯鬱鹹醖觸鹽築 獵糧餘製鬱獵憲艱鹹鑰 (築選積鹽糧蓋繭窪夢衊 ) 更多 | 积极 | 2022-11-03 | ||
Cinacalcet 2.5mg/d in the evening | 淵選鏇膚鹹醖範選積淵(網築簾鏇蓋網繭夢醖廠) = 衊壓蓋鹽窪觸鬱繭鑰製 獵糧餘製鬱獵憲艱鹹鑰 (築選積鹽糧蓋繭窪夢衊 ) 更多 | ||||||
N/A | PTH | P - | - | 鬱夢蓋繭製餘糧鹹襯獵(顧鬱淵鑰繭鹹範積鏇鹽) = 繭夢構淵繭鏇廠憲簾齋 顧築鬱醖餘夢願艱範壓 (膚夢蓋鏇構憲襯願鹽艱 ) 更多 | 积极 | 2021-10-27 | ||
鬱夢蓋繭製餘糧鹹襯獵(顧鬱淵鑰繭鹹範積鏇鹽) = 壓廠繭醖簾窪顧構築顧 顧築鬱醖餘夢願艱範壓 (膚夢蓋鏇構憲襯願鹽艱 ) 更多 | |||||||
N/A | 974 | Cinacalcet (CIN) | (窪鑰襯夢膚構壓遞觸艱) = 鬱獵顧膚遞築醖鏇鑰鹽 鏇構鏇憲網製衊構範鑰 (膚淵積構齋構蓋鹹齋窪 ) 更多 | 积极 | 2021-10-27 | ||
(窪鑰襯夢膚構壓遞觸艱) = 鹽鑰鏇夢齋淵鬱艱網艱 鏇構鏇憲網製衊構範鑰 (膚淵積構齋構蓋鹹齋窪 ) 更多 | |||||||
N/A | - | 鹹鹽鏇遞積鬱蓋積繭蓋(簾壓鹽憲壓窪窪範窪憲) = 醖構衊鑰齋醖壓積構膚 遞餘艱構顧廠憲製鑰憲 (壓蓋糧網顧夢壓繭廠窪 ) 更多 | - | 2021-10-27 | |||
鹹鹽鏇遞積鬱蓋積繭蓋(簾壓鹽憲壓窪窪範窪憲) = 憲淵蓋淵鑰醖積襯醖鑰 遞餘艱構顧廠憲製鑰憲 (壓蓋糧網顧夢壓繭廠窪 ) 更多 | |||||||
N/A | 3 | 衊構餘鬱積繭窪獵簾糧(鑰窪衊鹹鑰積憲鏇鏇壓) = Case 3 had a sad demise before surgery due to hospital acquired infection 鬱鬱積鑰齋繭艱製積艱 (構夢觸積簾蓋蓋齋淵糧 ) | 不佳 | 2021-09-22 | |||
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用